Literature DB >> 1531163

Recommendations for colorectal cancer screening in ulcerative colitis: a review of research from a single university-based surveillance program.

B A Lashner1.   

Abstract

Colorectal cancer screening in ulcerative colitis patients is a commonly accepted practice whose parameters are based on convention and not necessarily on the epidemiology of disease. This review summarizes previously published data from a single university-based surveillance program to estimate important screening parameters. The hazard rate (annual risk) of developing cancer was found to rise exponentially with disease duration and to be approximately 2% at 20 yr of disease and nearly 8% at 30 yr of disease. Older age at symptom onset was a significant risk factor for neoplasia. The lead time between the development of low-grade dysplasia and high-grade dysplasia or cancer was approximately 3 yr. Efficient scheduling of tests (maximum benefit for a given cost) implied that the screening test interval should be inversely proportional to the square root of the hazard rate. As the hazard rate increased with duration of disease, the screening interval should shorten accordingly. An historical cohort study demonstrated that the parameters used in our program were not associated with the anticipated result of reduced colorectal cancer mortality. A surveillance program should be tested that uses a more sensitive criterion for a positive test.

Entities:  

Mesh:

Year:  1992        PMID: 1531163

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  4 in total

Review 1.  Biology of colorectal cancer in ulcerative colitis.

Authors:  B A Lashner; B D Shapiro
Journal:  J Gastrointest Surg       Date:  1998 Jul-Aug       Impact factor: 3.452

Review 2.  Decision making in colorectal cancer screening.

Authors:  E Trowers; W Nguyen; E Cobos
Journal:  J Natl Med Assoc       Date:  1997-01       Impact factor: 1.798

3.  Utility of surveillance colonoscopy in ulcerative colitis.

Authors:  W H Kim; P M Choi
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

4.  A decision analysis of surveillance for colorectal cancer in ulcerative colitis.

Authors:  F Delcò; A Sonnenberg
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.